Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
12/08/2020
TA644: Entrectinib for treating NTRK fusion-positive solid tumours
12/08/2020
TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
12/08/2020
TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
12/08/2020
TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
11/08/2020
TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
11/08/2020
TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
11/08/2020
TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
11/08/2020
TA267: Ivabradine for treating chronic heart failure
11/08/2020
TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
11/08/2020
TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
11/08/2020
TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
11/08/2020
TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (replaced TA271)
11/08/2020
TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (replaced TA289)
10/08/2020
TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (replaced TA295)
10/08/2020
TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
10/08/2020
TA290: Mirabegron for treating symptoms of overactive bladder
10/08/2020
TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
05/08/2020
TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
05/08/2020
TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
05/08/2020
TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
3
4
5
6
7
8
9
10
11
12
13
Follow AWTTC: